Added to YB: 2026-09-11
Pitch date: 2026-09-09
CTMX [neutral]
CytomX Therapeutics, Inc.
Author Info
No bio for this author
Company Info
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment.
Market Cap
$771.4M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-5.51
P/E
-7.78
EV/Sales
24.41
Sector
Biotechnology
Category
growth
Wells Fargo Healthcare Conference Biotech day 1 Batch 3 - CytomX Therapeutics — CTMX 70/62
CTMX (update): CytomX is developing masked EPCAM-targeting ADC CX-2051 for late-line metastatic colorectal cancer, with expansion into other gastrointestinal tumors and combination studies. The efficacy narrative is encouraging, but actual response, progression-free-survival and durability data were not provided, while high-grade diarrhea remains the main safety issue. The year-end dataset should clarify efficacy, dose optimization, survival and whether toxicity is manageable.
Read full article (1 min)